← BackLABCORP HOLDINGS INC. · Medical LaboratoriesLH
Low riskNext report: In 0 days (est.)
The short versionA profitable company with steady sales.
Going well
- Profitable every year for 10 years
- Brings in more cash than it spends
- Buying back shares: share count down 8.5% in 3 years
Money moves
- No insider buying or selling in the last 30 days
- Institutions added 2.1% to their holdings in the quarter ending June 2026 (453 bought, 459 sold)
- Held by Ray Dalio (Bridgewater)
Facts from SEC filings, not a recommendation.
What the price means
Price as of Oct 26
$329.87+0.3% that day
- Company value
- $26.8B
- Share price times all shares
- Price vs profit (P/E)
- 27.3x
- You pay about $27 for each $1 of yearly profit
- Price vs sales
- 1.9x
- Company value is 1.9 times a year of sales
- Dividend yield
- 0.9%
- Yearly dividend as a share of today's price
- Cash vs value
- 1%
- Cash as a share of company value
- Debt vs value
- 21%
- Debt as a share of company value
From LH's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.
The business over time
Last 12 quarters, from SEC filings
Sales, Jun '26$3.7B+5.8% vs a year earlier
Sep '23Tap a barJun '26
Last 12 months: $14.3B, up 6.4% from the 12 months before. Over 5 years, sales grew about 0.0% a year.
Business quality
The checklist Warren Buffett-style investors use. Annual numbers for 2025.- MissReturn on equity 15%+Earns a lot on the money owners have in the business.10.5%
- MissDebt under half of equityNot relying on borrowed money.0.65x equity
- MissNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.6.3%
- PassProfitable every yearSteady profits, not one good year.10 of 10 years
- PassFree cash flow positiveBrings in more cash than it spends to run and grow.$1.2B
- PassShare count not growingNot diluting owners. Falling means buybacks.-8.5% in 3 years
- MissGross margin 40%+Pricing power: sells for well above what it costs to make.28.8%
- Revenue
- $14.0B
- +7.2% vs prior year
- 5-year growth
- 0.0%/yr
- revenue, per year
- Total debt
- $5.6B
- 0.65x equity
- Current ratio
- 1.42x
- short-term assets / bills due
From annual reports filed with the SEC. A checklist is a starting point for research, not a verdict.
Latest quarter
Quarter ended Jun 30, 2026- Revenue
- $3.7B
- +5.8% YoY
- EPS
- $3.64
- vs $2.84
- Op. margin
- 12.1%
- +0.9 pts
- Gross margin
- 29.8%
- +0.1 pts
- Free cash flow
- $313.9M
- Share count
- -2.3%
- vs a year ago
Insider rating
Last 90 days
No open-market insider buys or sells in the last 90 days.
Weekly insider trendNo trades to chart yet.
Filing buzz
Last 7 days vs normal
40/ 100
- This week
- 1
- Normal week
- 1.4
- vs normal
- 0.7x
SEC filings of any kind. 50 means a normal week.
Institutional ownership
■Steady+2.1%Institutions added 2.1% to their holdings. 453 bought, 459 sold.
Shares held by institutions79.5M
Sep '24Jun '26
Share count growthYearly rate, last 3 years
-2.9%Cash runwayAt last year's cash burn
Cash flow positiveDebt to equityLatest balance sheet: debt compared with what owners have
0.7x · $5.9B debtShares outstandingLatest reported
81MNext reportIn 0 days (est.)Estimated from the same quarter last year
- Results filedJul 30
- Results filedApr 30
- Results filedFeb 17
- Results filedOct 28, 2025
- Results filedJul 24, 2025
Flags and big holders
Offerings 6 months, flags 12 months, holders 90 days
No offerings, red flags or new big holders. Clean record.
Insider trades
Open-market buys and sells, last 90 days
No open-market buys or sells in 90 days. Grants and option exercises are left out.
"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.
Latest filings
Straight from SEC EDGAR
Stock awardBrian J CaveneyEVP, Pres of BLS, CMO & CSO
3,000 shares
- +72% of holdings
- Now owns 7,170 shares
- Restricted Stock Unit
- Filed 2 days after trade
Stock awardBryan T VaughnEVP and President, Diagnostics
1,500 shares
- +40% of holdings
- Now owns 5,204 shares
- Restricted Stock Unit
- Filed 2 days after trade
Stock awardJonathan C MeltzerEVP, COO
900 shares
- +33% of holdings
- Now owns 3,594 shares
- Restricted Stock Unit
- Filed 2 days after trade
Stock awardAkinbolade OyegunwaEVP, CIO & CTO
750 shares
- +34% of holdings
- Now owns 2,940 shares
- Restricted Stock Unit
- Filed 2 days after trade
SoldKerrii B AndersonDirector
3,000 shares at $318.02 · $954K
- -31% of holdings
- Now owns 6,563 shares
- Pre-planned sale (10b5-1)
- Filed 1 day after trade
SoldAdam H SchechterPresident & CEO, Director
4,669 shares at $320.37 · $1.5M
- -4% of holdings
- Now owns 102,565 shares
- Pre-planned sale (10b5-1)
- Filed 1 day after trade